Phenotypic and functional assessments of immune status in the rat spleen following acute heroin treatment

Immunopharmacology

Volumn 46, Issue 3, 2000, Pages 193-207

  Fecho, Karamarie ^a   Nelson, Christina J ^a   Lysle, Donald T ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Flow cytometry; Heroin; Immune system; Interferon ; Lymphocyte proliferation; Natural killer cells

Indexed keywords

DIAMORPHINE; GAMMA INTERFERON; NALTREXONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; IMMUNE STATUS; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; CONCANAVALIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; HEROIN; IMMUNE SYSTEM; IMMUNOPHENOTYPING; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; NALTREXONE; NARCOTICS; RATS; RATS, INBRED LEW; SPLEEN;

EID: 0033982451     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00175-7     Document Type: Article

References (73)

1. Battistini L., Borsellino G., Sawicki G., Poccia F., Salvetti M., Ristori G., Brosnan C.F. Phenotypic and cytokine analysis of human peripheral blood γδ T cells expressing NK cell receptors. J. Immunol. 159:1997;3723-3730.
2. Bayer B.M., Daussin S., Hernandez M., Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology. 29:1990;369-374.
3. Bolger G.T., Skolnick P., Rice K.C., Weissman B.A. Differential regulation of μ-opiate receptors in heroin- and morphine-dependent rats. FEBS Letters. 234:1988;22-26.
4. Brown G.P., Yang K., King M.A., Rossi G.C., Leventhal L., Chang A., Pasternak G.W. 3-Methoxynaltrexone, a selective heroin/morphine-6β-glucuronide antagonist. FEBS Letters. 412:1997;35-38.
5. Brown S.M., Stimmel B., Taub R.N., Kochwa S., Rosenfield R.E. Immunologic dysfunction in heroin addicts. Arch. Int. Med. 134:1974;1001-1006.
6. Bryant H.U., Bernton E.W., Holaday J.W. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci. 41:1987;1731-1738.
7. Bryant H.U., Roudebush R.E. Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J. Pharmacol. Exp. Ther. 255:1990;410-414.
8. Bussiere J.L., Adler M.W., Rogers T.J., Eisenstein T.K. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol. Immunotoxicol. 14:1992;657-673.
9. Carpenter G.W., Breeden L., Carr D.J.J. Acute exposure to morphine suppresses cytotoxic T-lymphocyte activity. Int. J. Immunopharmacol. 17:1995;1001-1006.
10. Carr D.J.J., Mayo S., Gebhardt B.M., Porter J. Central α-adrenergic involvement in morphine-mediated suppression of splenic natural killer activity. J. Neuroimmunol. 53:1994;53-63.
11. Chambers W.H., Vujanovic N.L., DeLeo A.B., Iszowy M.W., Herberman R.B., Hiserodt J.C. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J. Exp. Med. 169:1989;1373-1389.
12. Chao C.C., Sharp B.M., Pomeroy C., Filice G.A., Peterson P.K. Lethality of morphine in mice infected with Toxoplasma gondii. J. Pharmacol. Exp. Ther. 252:1990;605-609.
13. Cherubin C.E., Millian S.J. Serological investigations in narcotic addicts. Ann. Int. Med. 69:1968;739-742.
14. Clark W.M., Lauten J.D., Lessov N., Woodward W., Coull B.M. Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Mol. Chem. Neuropathol. 26:1995;213-230.
15. Cushman P., Grieco M.H. Hyperimmunoglobulinemia associated with narcotic addiction: effects of methadone maintenance treatment. Am. J. Med. 54:1973;320-326.
16. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science. 259:1993;1739-1742.
17. De Paoli P., Reitano M., Battistin S., Martelli P., Villalata D., Bergamo F., Tirelli U., Carbone A., Diodato S., Bosio R., Santini G. Immunological abnormalities in intravenous drug abusers and relationship to the prolonged generalized lymphadenopathy syndrome in Italy. Clin. Exp. Immunol. 64:1986;451-456.
18. Dijkstra C.D., Dopp E.A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunol. 54:1985;589-599.
19. Eisenstein T.K., Meissler J.J. Jr., Geller E.B., Adler M.W. Immunosuppression to tetanus toxoid induced by implanted morphine pellets. Ann. N. Y. Acad. Sci. 594:1990;377-379.
20. Fecho K., Lysle D.T. Phenotypic analysis of splenocyte subsets following acute morphine treatment in the rat. Cell. Immunol. 195:1999;137-146.
21. Fecho K., Maslonek K.A., Coussons-Read M.E., Dykstra L.A., Lysle D.T. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J. Immunol. 152:1994;5845-5852.
22. Flores L.R., Wahl S.M., Bayer B.M. Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on leukocyte trafficking. J. Pharmacol. Exp. Ther. 272:1995;1246-1251.
23. Fuchs B.A., Pruett S.B. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. J. Pharmacol. Exp. Ther. 266:1993;417-423.
24. Govitrapong P., Suttitum T., Kotchabhakdi N., Uneklabh T. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J. Pharmacol. Exp. Ther. 286:1998;883-889.
25. Güngör M., Genç E., Sagduyu H., Eroglu L., Koyuncuoglu H. Effect of chronic administration of morphine on primary immune response in mice. Experientia. 36:1980;1309-1310.
26. Hamid A., Curtis R., McCoy K., McGuire J., Conde A., Bushell W., Lindenmayer R., Brimberg K., Maia S., Abdur-Rashid S., Settembrino J. The heroin epidemic in New York City: current status and prognoses. J. Psychoact. Drugs. 29:1997;375-391.
27. Hamra J.G., Yaksh T.L. Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen-induced proliferation in rat lymphocytes. Anesthesiology. 85:1996;355-365.
28. Ho W.K.K., Leung A. The effect of morphine addiction on concanavalin A-mediated blastogenesis. Pharmacol. Res. Commun. 11:1979;413-419.
29. Hilburger M.E., Adler M.W., Truant A.L., Meissler J.J. Jr., Satishchandran V., Rogers T.J., Eisenstein T.K. Morphine induces sepsis in mice. J. Infect. Dis. 176:1997;183-188.
30. Hussey H.H., Katz S. Infections resulting from narcotic addiction. Am. J. Med. 9:1950;186-193.
31. Hutto C.W., Crowder W.F. Dosage choices of rats for morphine, for heroin, and between morphine and heroin. Pharmacol. Biochem. Behav. 58:1997;133-140.
32. Ishikawa M., Tanno K., Kamo A., Takayanagi Y., Sasaki K. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol. Pharm. Bull. 16:1993;762-766.
33. Jasinski D.R., Preston K.L. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend. 17:1986;301-310.
34. Kaiko R.F., Wallenstein S.L., Rogers A.G., Grabinski P.Y., Houde R.W. Analgesic and modd effects of heroin and morphine in cancer patients with postoperative pain. N. Engl. J. Med. 304:1981;1501-1505.
35. Lamas X., Negus S.S., Gatch M.B., Mello N.K. Effects of heroin/cocaine combinations in rats trained to discriminate heroin or cocaine from saline. Pharmacol. Biochem. Behavior. 60:1998;357-364.
36. Lazzarin A., Mella L., Trombini M., Uberti-Foppa C., Franzetti F., Mazzoni G., Galli M. Immunological status in heroin addicts: effects of methadone maintenance treatment. Drug Alcohol Depend. 13:1984;117-123.
37. Lefkowitz S.S., Chiang C.Y. Effects of certain abused drugs on hemolysin forming cells. Life Sci. 17:1975;1763-1768.
38. Lockwood L.L., Silbert L.H., Fleshner M., Laudenslager M.L., Watkins L.R., Maier S.F. Morphine-induced decreases in in vivo antibody responses. Brain Behav. Immun. 8:1994;24-36.
39. Louria D.B., Hensle T., Rose J. The major medical complications of heroin addiction. Ann. Intern. Med. 67:1967;1-22.
40. Luttgens W.F. Endocarditis in "main line" opium addicts. Arch. Int. Med. 83:1949;653-664.
41. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., Dykstra L.A. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1993;1071-1078.
42. Martin T.J., Smith J.E., Dworkin S.I. Training dose and session time as contextual determinants of heroin self-administration in rats. Pharmacol. Biochem. Behavior. 60:1998;415-421.
43. Martin T.J., Walker L.E., Sizemore G.M., Smith J.E., Dworkin S.I. Within-session determination of dose-response curves for heroin self-administration in rats: comparison with between-session determination and effects of naltrexone. Drug Alcohol Depend. 41:1996;93-100.
44. Martin W.R., Fraser H.F. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts. J. Pharmacol. Exp. Ther. 133:1961;388-399.
45. McDonough R.J., Madden J.J., Falek A., Shafer D.A., Pline M., Gordon D., Bokos P., Kuehnle J.C., Mendelson J. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes. J. Immunol. 125:1980;2539-2543.
46. Millian S.J., Cherubin C.E. Serological investigations in narcotic addicts: III. Latex fixation, C-reactive protein, "Monotest", serum proteins and SH antigen. Am. J. Clin. Pathol. 56:1971;693-698.
47. Mohs M.E., Watson R.R., Leonard-Green T. Nutritional effects of marijuana, heroin, cocaine, and nicotine. J. Am. Diet. Assoc. 90:1990;1261-1267.
48. Nair M.P.N., Laing T.J., Schwartz S.A. Decreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers. Clin. Immunol. Immunopathol. 38:1986;68-78.
49. Nelson C.J., Dykstra L.A., Lysle D.T. Comparison of the time course of morphine's analgesic and immunologic effects. Anesth. Analg. 85:1997;620-626.
50. Novick D.M., Ochshorn M., Chali V., Croxson T.S., Mercer W.D., Chiorazzi N., Kreek M.J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250:1989;606-610.
51. Novick D.M., Ochshorn M., Kreek M.J. In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts. Adv. Exp. Med. Biol. 288:1991;159-170.
52. Oldendorf W.H., Hyman S., Braun L., Oldendorf S.Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 178:1972;984-986.
53. Ottaway C.A., Husband A.J. Central nervous system influences on lymphocyte migration. Brain Behav. Immun. 6:1992;97-116.
54. Page G.G., Ben-Eliyahu S., Liebeskind J.C. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav. Immun. 8:1994;241-250.
55. Rady J.J., Aksu F., Fujimoto J.M. The heroin metabolite, 6-monoacetylmorphine, activates delta opioid receptors to produce antinociception in Swiss-Webster mice. J. Pharmacol. Exp. Ther. 268:1994;1222-1231.
56. Rady J.J., Roerig S.C., Fujimoto J.M. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception. J. Pharmacol. Exp. Ther. 256:1991;448-457.
57. Robinson S.L., Rowbotham D.J., Smith G. Morphine compared with diamorphine: a comparison of dose requirements and side-effects after hip surgery. Anaesthesia. 46:1991;538-540.
58. Rossi G.C., Brown G.P., Leventhal L., Yang K., Pasternak G.W. Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesia. Neurosci. Lett. 216:1996;1-4.
59. Roy S., Ramakrishnan S., Loh H.H., Lee N.M. Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur. J. Pharmacol. 195:1991;359-363.
60. Ryan J.C., Niemi E.C., Nakamura M.C., Seaman W.E. Specific receptor that activates natural killer cell cytotoxicity. J. Exp. Med. 181:1995;1911-1915.
61. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. U.S.A. 83:1986;7114-7117.
62. Singhal P.C., Reddy K., Frankl N., Sanwal V., Gibbons N. Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B. Inflammation. 21:1997;609-617.
63. Starec M., Rouveix B., Sinet M., Chau F., Desforges B., Pocidalo J.-J., Lechat P. Immune status and survival of opiate- and cocaine-treated mice infected with Friend virus. J. Pharmacol. Exp. Ther. 259:1991;745-750.
64. Substance Abuse and Mental Health Services Administration, Department of Health and Human Services: 1997 National Household Survey on Drug Abuse, Publication No. (SMA) 98-3251, 1998 (http://www.samhsa.gov).
65. Swan N. CDC report highlights link between drug abuse and spread of HIV. NIDA Notes. 12:1997;7.
66. Thomas P.T., House R.V., Bhargava H.N. Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen. Pharmacol. 26:1995;123-130.
67. Tubaro E., Borelli G., Croce C., Cavallo G., Santiangeli C. Effect of morphine on resistance to infection. J. Infect. Dis. 148:1983;656-666.
68. van Goor H., Fidler V., Weening J.J., Grond J. Determinations of focal and segmental glomerulosclerosis in the rat after renal ablation. Lab. Invest. 64:1991;754-765.
69. Vogel H., Cherubin C.E., Millian S.J. Serological investigations in narcotic addicts: II. Febrile agglutinins. Am. J. Clin. Pathol. 53:1970;932-935.
70. Way E.L., Kemp J.W., Young J.M., Grassetti D.R. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J. Pharmacol. 129:1960;144-154.
71. Way E.L., Young J.M., Kemp J.W. Metabolism of heroin and its pharmacologic implications. Bull. Narc. 17:1963;25-33.
72. Weber R.J., Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science. 245:1989;188-190.
73. Yin D., Mufson R.A., Wang R., Shi Y. Fas-mediated cell death promoted by opioids. Nature. 397:1999;218.